You are here: Industry Insights > Rinvoq

News List

FDA Approves Rinvoq for Treatment of Atopic Dermatitis drugs.com
January 19, 2022
The U.S. Food and Drug Administration approved Rinvoq (upadacitinib) for the treatment of moderate-to-severe...
The NICE recommends Rinvoq for psoriatic arthritis patients pharmatimes
January 10, 2022
The chronic, inflammatory disease affects an estimated 24 in every 10,000 people.
Rinvoq® shows positive results in rheumatoid arthritis post-hoc analysis EuropeanPharmaceuticalReview
November 10, 2021
AbbVie has announced new results from a post-hoc analysis of the Phase III SELECT-BEYOND clinical trial evaluating Rinvoq® (upadacitinib; 15mg, once daily) in patients with moderate...
AbbVie's Rinvoq cleared in EU for atopic dermatitis firstwordpharma
August 25, 2021
AbbVie announced Tuesday that the European Commission has expanded the label for Rinvoq (upadacitinib) to include treating moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
AbbVie's 2Q Revenue up 34% contractpharma
August 02, 2021
New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.
Rinvoq scores positive results as a maintenance therapy for ulcerative colitis pharmatimes
July 02, 2021
AbbVie’s JAK inhibitor Rinvoq met the primary and all secondary endpoints in a Phase III ulcerative colitis maintenance study, the company announced earlier this week.
Abbvie's 1Q Reveneus up 51% contractpharma
May 06, 2021
Aesthetics portfolio drives growth in the quarter with Botox Cosmetic sales up 45%.
USFDA extends review period for AbbVie’s sNDA of upadacitinib pharmaceutical-business-review
March 18, 2021
The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.
AbbVie's Rinvoq bags two new EU approvals pharmatimes
January 27, 2021
The European Commission (EC) has approved AbbVie’s Rinvoq (upadacitinib) for the treatment of active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
CHMP Recommends Approvals of RINVOQ for the Active Psoriatic Arthritis, Ankylosing Spondylitis americanpharmaceuticalreview
December 31, 2020
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ™ (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor, for the expanded ...

Previous page 1 2 3 Next page